Depression: all studies (page 65) - The Consciousness Library

Rewiring the Aging Mind: A Randomized Controlled Trial on the Transformative Impact of Mindfulness-based Cognitive Behavioural Therapy on Depression and Anxiety

Journal of Ecophysiology and Occupational Health December 2, 2025 Rachna Garg, Shubhagata Awasthi, Naveen Gupta

The rising incidence of depression and anxiety among the elderly is a growing public health concern. While pharmacological treatments are widely used, they often present challenges such as side effects and dependency, highlighting the need for evidence-based psychotherapeutic alternatives. Mindfulness-Based Cognitive Behavioral Therapy (MBCBT) integrates mindfulness techniques with cognitive...

DOI: 10.18311/jeoh/2025/49565

Nitrous oxide for the treatment of depression: a systematic review and meta-analysis.

EBioMedicine December 1, 2025 Kiranpreet Gill, Angharad N De Cates, Chantelle Wiseman et al.

Depression remains a global public health challenge, prompting interest in translational targets which allow for more effective and rapidly acting interventions. Nitrous oxide (N2O), an N-methyl-d-aspartate receptor antagonist, has demonstrated potential as a rapid-acting antidepressant. This study synthesised existing data on the efficacy and safety of N2O in depressive disorders. We...

DOI: 10.1016/j.ebiom.2025.106023 Full text Major depressive disorder Treatment-resistant depression Antidepressant N-methyl-d-aspartate receptor +1

Rethinking Treatment-Resistant Depression: A Systematic Review of Novel Therapeutic Strategies and Precision Medicine Approaches.

Actas Españolas de Psiquiatría December 1, 2025 Safiye Zeynep Tatlı, Murat İlhan Atagün 2 citations

Treatment-resistant depression (TRD) is a complex and heterogeneous condition affecting a considerable subset of patients who do not respond to conventional antidepressants. Given the limitations of traditional treatment strategies, there is a growing need for alternative and personalized approaches. This review explores the neurobiological underpinnings of TRD and examines the efficacy of...

DOI: 10.62641/aep.v53i6.1946 Full text

Personalizing ketamine therapy: Real-world predictors of response to IV ketamine and intranasal esketamine in treatment-resistant depression.

Psychiatry Research December 1, 2025 Ahmed Z Elmaadawi, Imane Naha, Shruti Prabhudesai et al. 2 citations

Treatment-resistant depression (TRD) poses significant clinical challenges, often necessitating alternative treatments such as intravenous (IV) ketamine or intranasal esketamine. This study compared the effectiveness of these modalities and examined predictors of treatment response, including comorbidity profile, prior antidepressant failures, age, and gender. A retrospective chart review was...

DOI: 10.1016/j.psychres.2025.116821 Full text Depression Esketamine Retrospective Trd

The relationship between 3,4-methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid-30s: Findings from the Victorian Adolescent Health Cohort Study.

Addiction December 1, 2025 Zachary Bryant, Kirsten Morley, Jessica A Kerr et al.

MDMA (3,4-methylenedioxymethamphetamine or "Ecstasy") is the fourth-most used illicit substance globally. While previous research found links between MDMA use and mental health outcomes, the direction and nature of this relationship remain unclear. This study assessed whether MDMA use in early adulthood increases the risk of anxiety or depression in mid-30s. A longitudinal, population-based...

DOI: 10.1111/add.70173 Full text MDMA Anxiety Depression 3,4‐methylenedioxymethamphetamine +5

Qualitative content analysis of expectations in participants with depression about to begin LSD microdosing treatment: Identifying the need for psychedelic expectancy measures.

Neuropharmacology December 1, 2025 Carina Joy Donegan, Dimitri Daldegan-Bueno, Tehseen Noorani et al. 4 citations

Expectations can impact antidepressant treatment and psychedelic therapy, often enhancing placebo effects and influencing outcomes. However, research in this context is lacking. Our study explored the expectations of participants with major depressive disorder (MDD) before microdosing lysergic acid diethylamide (LSD) in an open-label trial. Twenty-three individuals with MDD completed a...

DOI: 10.1016/j.neuropharm.2025.110670 Full text Depression LSD Microdosing Expectancy +4

Ketamine infusion therapy for treatment-resistant major depressive disorder and suicidal ideation: Nursing care and considerations.

Nursing December 1, 2025 Rebecca Ann Ivory, Kathryn M. Pate, Brentyn M Jones et al.

Major depressive disorder (MDD) affects approximately 332 million people worldwide. Among those diagnosed with MDD, approximately 53% receive pharmacologic treatment, such as ketamine. Nurses must be knowledgeable about ketamine and other emerging, effective behavioral health therapies used to treat chronically depressed mood and acute suicidal ideation. This article outlines the best nursing...

DOI: 10.1097/NSG.0000000000000306 Full text Esketamine Major depressive disorder Mdd Treatment-resistant depression +12

Efficacy of intranasal esketamine versus rTMS for treatment-resistant depression: analysis of individual participant data from two clinical trials.

EClinicalMedicine December 1, 2025 Tyler S Kaster, Yi Dai, Fidel Vila-Rodriguez et al. 5 citations

Repetitive transcranial magnetic stimulation (rTMS) and intranasal esketamine are effective treatment options for treatment-resistant depression (TRD) that have not been directly compared. We aimed to compare the effectiveness of rTMS, intranasal esketamine, and pharmacotherapy for TRD using data from two randomised clinical trials (RCTs). This secondary analysis of individual patient data...

DOI: 10.1016/j.eclinm.2025.103609 Full text Depressive disorder Esketamine Treatment-resistant depression Clinical trials +3

The effect of low-dose esketamine on maternal depression after cesarean delivery.

Journal of psychosomatic obstetrics and gynaecology December 1, 2025 Yan Shang, Siyuan Li, Qin Zheng et al. 8 citations

To assess the impact of low-dose intravenous esketamine on postpartum depression scores in women undergoing cesarean section. In a randomized, double-blind, placebo-controlled trial, 186 women aged 20-50 years receiving epidural anesthesia for cesarean section were divided into three groups: Group A (0.25 mg/kg esketamine intraoperatively + esketamine in PCIA), Group B (0.25 mg/kg esketamine...

DOI: 10.1080/0167482X.2025.2527659 Full text Esketamine Epds Cesarean section Patient-controlled intravenous analgesia +3

Psychedelic interventions for major depressive disorder in the elderly: Exploring novel therapies, promise and potential.

Dialogues in Clinical Neuroscience December 1, 2025 Ivona-Maria Tudorancea, Gabriela-Dumitrita Stanciu, Carla Torrent et al. 4 citations

The global population is ageing rapidly, with the number of individuals aged 60 and older reaching 1 billion in 2019 and expected to double by 2050. As people age, neuropsychological health often deteriorates, leading to a higher prevalence of age-related depression. Symptoms may include anxiety, apathy, mood instability, sadness, and, in severe cases, suicidal thoughts. Depression in the...

DOI: 10.1080/19585969.2025.2499458 Full text Psychedelic-assisted therapy Age-related comorbidities Ageing and depression Mental health care +6